UK launches pilot schemes to speed patient access to new medicines

New pilot schemes announced by the UK government will test new approaches to medicines access, pricing and adoption, with the aim of reducing the time it takes for innovative therapies to reach NHS patients. The initiative builds on recent NICE reforms that have already expanded access to several additional medicines.

The Baseline

• The UK government has announced pilot schemes that will test new approaches to medicines pricing, access and adoption, with implementation expected to begin in September 2026.
• The initiative builds on April 2026 changes to NICE's cost-effectiveness threshold, which have already resulted in nine additional medicines being recommended for NHS use.
• One pilot will evaluate earlier access to innovative therapies, including treatments for rare diseases, while others will examine productivity-based value assessment, industry co-investment and regional funding to improve uptake.

The UK government is introducing a series of pilot schemes intended to accelerate NHS patient access to innovative medicines while evaluating new approaches to pricing, reimbursement and adoption. Developed by a joint taskforce involving government, the NHS, the pharmaceutical industry and patient organizations, the pilots are expected to begin as early as September. Four pilot approaches will be evaluated between September 2026 and September 2027, each involving a small cohort of selected medicines.

The initiative delivers commitments set out in the UK–US pharmaceutical arrangement and forms part of the government's wider ambition to strengthen the UK's life sciences sector while improving access to new treatments across the NHS.

One pilot will explore ways to provide eligible NHS patients with faster access to innovative medicines that have already demonstrated safety, quality and clinical effectiveness. The approach will include therapies for rare conditions, where delays between regulatory approval and routine patient access can have significant consequences.

Although the government has not yet published details of how the pilot will operate, it is expected to explore approaches for managing uncertainty where conventional evidence generation may be challenging. This could include examining the role of real-world data (RWD) in supporting earlier patient access, particularly for rare disease therapies where randomized, large-scale clinical trials are often impractical.

Additional pilots will evaluate new approaches to medicines assessment and adoption. These include incorporating the productivity benefits of new medicines, such as enabling patients to return to work, mechanisms allowing industry to co-invest in screening, testing and broader patient care pathways to support faster implementation of NICE recommendations, and dedicated regional funding intended to improve uptake of priority medicines across local health systems.

The announcement builds on changes to the NICE cost-effectiveness threshold implemented in April 2026. According to the Department of Health and Social Care, the revised threshold has already resulted in nine additional medicines being recommended for NHS patients in England and Wales.

The newly approved treatments cover a range of serious conditions, including blood disorders, autoimmune diseases and several cancers, including pediatric brain tumors and advanced gastric cancer. As the revised arrangements become established, NICE estimates that up to five additional medicines could be recommended each year compared with the previous framework, while continuing its record of recommending more than 90% of medicines it evaluates.

The pilots have been welcomed by patient organizations, particularly those representing people living with rare diseases. Genetic Alliance UK noted the faster access pilot could be especially important for patients with progressive conditions, where the period between MHRA approval and completion of a NICE appraisal can delay access to treatment. The organization’s Chief Executive, Nick Meade, said:

"Getting treatments into managed access programs without waiting for a full NICE assessment could mean people get treated months earlier. This time saved has the real potential to save lives."

The organization also said the approach could also enable greater use of the Innovative Medicines Fund by allowing eligible medicines to enter managed access arrangements sooner.

Meade added that allowing eligible medicines to move directly from MHRA approval into managed access arrangements could make greater use of the existing Innovative Medicines Fund while addressing some of the evidence challenges faced by rare disease therapies, where generating large-scale clinical evidence is often difficult because of small patient populations.

The government said the pilots support its longer-term commitment to increase spending on innovative medicines from 0.3 to 0.6% of GDP over the next decade. Outcomes from the pilot schemes are expected to inform future approaches to medicines access while supporting both NHS adoption of innovative therapies and continued investment in UK life sciences.

However, the announcement comes amid broader discussion about the long-term implications of the UK–US pharmaceutical arrangement. While the government has argued that increased investment will improve patient access and strengthen the UK's life sciences sector, recent independent analysis published in the BMJ has suggested the policy could substantially increase NHS medicines expenditure over the next decade, highlighting the importance of ensuring that faster access is accompanied by robust approaches to evidence generation, value assessment and reimbursement.